Home > Products > Featured products

DT2216

  Cat. No.:  DC28671   Featured
Chemical Structure
2365172-42-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
DT2216 is a selective B-cell lymphoma extra large (BCL-XL) proteolysis-targeting chimera (PROTAC). DT2216 targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 2365172-42-3
Synonyms: DT2216;DT-2216;DT 2216
SMILES: CC1(CC(CN2CCN(C3C=CC(C(=O)NS(=O)(C4C=CC(N[C@H](CCN5CCN(C(=O)CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6C=CC(C7SC=NC=7C)=CC=6)C(C)(C)C)CC5)CSC5C=CC=CC=5)=C(S(=O)(=O)C(F)(F)F)C=4)=O)=CC=3)CC2)=C(C2C=CC(Cl)=CC=2)CC1)C
Formula: C77H96ClF3N10O10S4
M.Wt: 1542.35
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication: [1]. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.
Description: DT2216 is a selective B-cell lymphoma extra large (BCL-XL) proteolysis-targeting chimera (PROTAC). DT2216 targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets[1].
Target: VHL
In Vivo: DT2216 (i.p.; 7.5, 15 mg/kg; weekly for 60 days) of 15 mg/kg is more effective at suppressing the growth of MOLT-4 T-ALL xenografts in mice than 7.5 mg/kg[1]. Animal Model: CB17/Icr-Prkdcscid/IcrIcoCrl (CB-17 SCID) mice aged 5-6 weeks[1] Dosage: 7.5, 15 mg/kg Administration: i.p.; weekly for 60 days Result: Suppressed the growth of MOLT-4 T-ALL xenografts in mice.
In Vitro: DT2216 (62.5, 125 nM; 72 hours) kills MOLT-4 cells[1]. ABT263 (0.001-10 μM; 72 hour) shows highly toxic to MOLT-4 cells with an EC50 of 0.052 μM[1]. DT2216 (0.1, 0.3 μM; 24 hours) kills MOLT-4 cells by caspase-3-mediated induction of apoptosis in a BCL-2 homologous antagonist killer (BAK)- and BCL-2-associated X protein (BAX)-dependent manner[1]. Apoptosis Analysis[1] Cell Line: MOLT-4 cells Concentration: 62.5, 125 nM Incubation Time: 72 hours Result: Killed MOLT-4 cells. Cell Cytotoxicity Assay[1] Cell Line: MOLT-4 cells Concentration: 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Showed highly toxic to MOLT-4 cells with an EC50 of 0.052 μM. Western Blot Analysis[1] Cell Line: MOLT-4 cells Concentration: 0.1, 0.3 μM Incubation Time: 24 hours Result: Killed MOLT-4 cells by caspase-3-mediated induction of apoptosis in a BCL-2 homologous antagonist killer (BAK)- and BCL-2-associated X protein (BAX)-dependent manner.
References: [1]. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.
MSDS
TITLE DOWNLOAD
MSDS_12723_DC28671_2365172-42-3
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC39826 Homo-PROTAC cereblon degrader 1 Homo-PROTAC cereblon degrader 1, is a cereblon degrader.
DC74523 XY-07-35 XY-07-35 is a potent, selective HDAC6 proteolysis targeting chimera (PROTAC) degrader with IC50 of 48.5 nM.
DC74503 KH-103 KH-103 is a highly potent, catalytically-driven glucocorticoid receptor (GR) PTORAC degrader, demonstrate excellent performance in passively preventing ligand-induced gene expression activation in the absence of partial agonistic transcriptional triggerin
DC72756 JQAD1 JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
DC50038 PROTAC SGK3 degrader-1 PROTAC SGK3 degrader-1 (SGK3-PROTAC1), is a potent SKG3 degrader based on PROTAC. PROTAC SGK3 degrader-1 (0.3 μM) induces 50% degradation of endogenous SGK3 within 2 hours, with maximal 80% degradation observed within 8 hours, accompanied by a loss of phosphorylation of NDRG1 (an SGK3 substrate).
DC48434 TD-165 TD165(TD 165) is a PROTAC-based cereblon (CRBN) degrader that degrads Cav1.2α with the DC50 of 20.4 nM, comprising a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.
DC47884 TLR4-IN-C34-C2-COOH TLR4-IN-C34-C2-COO is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
DC46405 ARD-2128 ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
DC46309 Boc-piperazine-benzoic acid Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128.
DC45754 ACBI1 ACBI1 is a potent and cooperative PROTAC degrader of SMARCA2, SMARCA4 and PBRM1 with DC50 of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 induces anti-proliferative effects and apoptosis.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia